INIA Biosciences

Executive Summary

INIA Biosciences is an early-stage medical device company pioneering non-invasive, home-administered bioelectronic therapies that use ultrasound to modulate the immune system. Founded in 2018 and headquartered in San Diego, the company focuses on treating chronic inflammatory diseases and oncology conditions with closed-loop devices. INIA's approach aims to replace or complement pharmacological interventions by harnessing sound waves to precisely regulate immune responses. While pre-revenue and with limited public data, the company's technology addresses large markets in inflammation and cancer. Key risks include early-stage development, regulatory unknowns, and lack of clinical validation. INIA's potential lies in its novel modality, which could offer safer, convenient, and cost-effective alternatives to systemic drugs. The company's progress will depend on advancing its platform through preclinical studies, securing partnerships, and raising capital. With no disclosed funding or pipeline, INIA remains a high-risk, high-reward opportunity in the bioelectronic medicine space.

Upcoming Catalysts (preview)

• Q1 2027FDA Breakthrough Device Designation for Lead Indication30% success
• H2 2027First-in-Human Clinical Trial Initiation25% success
• Q4 2026Series A Funding Round Announcement50% success